GA-binding protein subunit alpha (GABPA) (GABPA)

GA-binding protein subunit alpha (GABPA) is a critical transcription factor belonging to the ETS family, primarily known for its role in coordinating the expression of nuclear-encoded mitochondrial genes and ribosomal proteins [1, 5]. It functions as the DNA-binding component of the GABP complex, typically forming a heterotetramer with GABPB subunits to regulate energy metabolism and cell cycle progression [4, 5]. In clinical oncology, GABPA has emerged as a pivotal player in the maintenance of telomere length in cancers harboring TERT promoter mutations, such as glioblastoma and melanoma [3]. These mutations create de novo binding sites for GABPA, which then drives the overexpression of telomerase, enabling replicative immortality [2, 3]. Although GABPA is considered a high-priority therapeutic target for these specific malignancies, its essential role in normal mitochondrial function poses significant challenges for systemic inhibition [4]. Currently, there are no FDA-approved drugs that specifically target GABPA, though research into disrupting its interaction with the TERT promoter or its subunit dimerization is ongoing [3].

Other names

GABP alphaNuclear respiratory factor 2NRF2E4TF1AE4TF1-60Transcription factor E4TF1-60GABP-alpha

Binds to GA-rich DNA sequences (ETS binding sites) and recruits GABPB subunits to form a transcriptionally active heterotetramer that initiates gene transcription.